



Brian H. Rubenstein  
Tel: (215) 988-7864  
Fax: (215) 689-4419  
[rubensteinb@gtlaw.com](mailto:rubensteinb@gtlaw.com)

July 15, 2020

**VIA E-MAIL ONLY TO** [valpec@kirtlandpackard.com](mailto:valpec@kirtlandpackard.com)

Ruben Honik  
David Stanoch  
Golomb & Honik, P.C.  
1835 Market Street  
Suite 2900  
Philadelphia, PA 19103  
[rhonik@golombhonik.com](mailto:rhonik@golombhonik.com)  
[dstanoch@golombhonik.com](mailto:dstanoch@golombhonik.com)

Adam Slater  
Mazie Slater Katz & Freeman, LLC  
103 Eisenhower Parkway  
Suite 207  
Roseland, NJ 07068  
[aslater@mazieslater.com](mailto:aslater@mazieslater.com)

Daniel Nigh  
Levin Papantonio Thomas Mitchell Rafferty  
& Proctor, P.A.  
316 S. Baylen  
Suite 600  
Pensacola, FL 32502  
[dnigh@levinlaw.com](mailto:dnigh@levinlaw.com)

Conlee Whiteley  
Kanner & Whiteley, LLC  
701 Camp Street  
New Orleans, LA 70130  
[c.whiteley@kanner-law.com](mailto:c.whiteley@kanner-law.com)

Behram Parekh  
Kirtland & Packard LLP  
1638 South Pacific Coast Hwy  
Redondo Beach, CA 90277  
[bvp@kirtlandpackard.com](mailto:bvp@kirtlandpackard.com)

**Re: *In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation.*,  
U.S. District Court for the District of New Jersey; Case No. 1:19-md-02875-  
RBK-JS**

Dear Counsel:

This correspondence confirms Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd., Actavis LLC, Actavis Pharma, Inc., and Arrow Pharm (Malta) Ltd.<sup>1</sup> (collectively, “the Teva Defendants”) are today producing their first rolling production of documents required to be produced pursuant to the Court’s December 23, 2019 Order (DN 328), as modified by the

---

<sup>1</sup> Undersigned counsel notes that Arrow Pharm (Malta) Ltd. has not been served, and no longer exists as a separate legal entity. This production does not represent Arrow Pharm (Malta) Ltd. or any successor in interest’s consent to jurisdiction in this or any underlying matter, and Arrow Pharm (Malta) Ltd. and its successor in interest specifically reserve the right to raise any and all defenses, jurisdictional or otherwise.

Ruben Honik  
David Stanoch  
Adam M. Slater  
Conlee Whiteley  
Daniel Nigh  
Behram Parekh  
July 15, 2020  
Page 2

Court's April 20, 2020 Text Order (DN 416) and the Stipulation and Order Regarding ESI Search Terms as to the Teva Defendants (DN 493).

Moreover, consistent with the Court's directive, the Teva Defendants have used reasonable good faith efforts to comply with Plaintiffs' requested prioritization and to produce responsive documents in the possession of the Teva Defendants' attorneys and/or ESI consultants as of the Court's April 20, 2020 Text Order. As requested in Plaintiffs' May 7, 2020 letter, as clarified and supplemented by Plaintiffs' May 21, 2020 letter, the Teva Defendants production includes the following categories of non-custodial prioritized documents requested of the finished dose manufacturers<sup>2</sup>:

- Quality Supplier Agreements for the sale of Valsartan API (See RFPD Nos. 6, 10, 25, 96, 97, 98);
- Validation Specifications associated with Valsartan API (See RFPD Nos. 10, 19, 20, 21, 22);
- Certificate of Analyses associated with Valsartan API (See RFPD Nos. 10, 19, 20, 21, 22, 26);
- OOS and OOT reports, and any root cause analyses, as a result of Valsartan API testing and/or validation (See RFPD Nos. 10, 19, 20, 21, 22).

Additionally, with respect to the prioritized ESI productions, the Teva Defendants have made good faith efforts to prioritize and produce documents from the custodial files of Plaintiff's prioritized list of the Court-ordered Teva custodians whose custodial files were in the possession of Teva's attorneys and/or consultants as of the Court's April 20, 2020 Order (DN 416).

Specifically, this production is composed of the following documents:

Vol No.	Bates Range	Description	Source
015	TEVA-MDL2875-00019958 - TEVA-MDL2875-00020279	Non-custodial documents including Quality Supplier Agreements for the Sale of Valsartan API; Validation Specifications associated with Valsartan API; Certificate of Analyses associated with Valsartan	Non-custodial files

<sup>2</sup> The Teva Defendants' "Foreign Regulatory Documents" (RFPD Nos. \_56, 57) were previously produced as part of the Court-ordered core discovery. The remaining categories listed in Plaintiffs' prioritization letter—"Quality Supplier Agreements for services provided by solvent recovery vendors and outside laboratories used for the manufacture of Valsartan API or testing of Valsartan API" and "API Manufacturing Quality Assurance Documents" are directed at the API manufacturers and are not applicable to the Teva Defendants.

Ruben Honik  
David Stanoch  
Adam M. Slater  
Conlee Whiteley  
Daniel Nigh  
Behram Parekh  
July 15, 2020  
Page 3

		API; OOS and OOT reports, and any root cause analyses, as a result of Valsartan API testing and/or validation	
015	TEVA-MDL2875-00020280 - TEVA-MDL2875-00024621	Custodial Email files	Dan Baretto
015	TEVA-MDL2875-00024622 - TEVA-MDL2875-00035724	Custodial Email files	David Bonilla
015	TEVA-MDL2875-00035725 - TEVA-MDL2875-00040052	Custodial Email files	Joerg Fluch
015	TEVA-MDL2875-00040053 - TEVA-MDL2875-00040156	Custodial Email files	Elisabeth Gray
015	TEVA-MDL2875-00040157 - TEVA-MDL2875-00051260	Custodial Email files	Claire Lyons
015	TEVA-MDL2875-00051261 - TEVA-MDL2875-00056296	Custodial Email files	Jens Nassall
015	TEVA-MDL2875-00056297 - TEVA-MDL2875-00056337	Custodial Email files	Kiril Pavlov
015	TEVA-MDL2875-00056338 - TEVA-MDL2875-00063530	Custodial Email files	Corey Sawyer
015	TEVA-MDL2875-00063531 - TEVA-MDL2875-00066288	Custodial Email files	Constance Truemper
015	TEVA-MDL2875-00066289 - TEVA-MDL2875-00066609	Custodial Email files	Christopher Unger

Ruben Honik  
David Stanoch  
Adam M. Slater  
Conlee Whiteley  
Daniel Nigh  
Behram Parekh  
July 15, 2020  
Page 4

This production is being delivered to Plaintiffs' counsel identified above from Teva's vendor via a File Transfer Protocol ("FTP") link sent separately via email. The password for accessing the FTP documents will follow by separate email.

The documents are produced subject to the Court's June 26, 2019, Confidentiality and Protective Order (DN 139), and are subject to all of the rights and limitations imposed by the terms of that Order. The documents designated "CONFIDENTIAL" are not to be disclosed in any fashion, nor be used for any purpose other than the analysis and preparation for trial of this action, and shall not otherwise be disclosed or made available. To the extent the produced documents are marked as "RESTRICTED CONFIDENTIAL,"<sup>3</sup> such documents accordingly shall further be disclosed only to outside counsel and shall not be disclosed to any Party, a Party's witnesses, or in-house counsel except as permitted by the terms of the Confidentiality and Protective Order.

In addition, please note the enclosed documents are being produced pursuant to federal discovery rules. Production of the enclosed documents is not, and should not be considered, in any manner whatsoever, a waiver of the Teva Defendant's rights, privileges or defenses, including their rights under federal law to object to the relevance or admissibility of the documents or information contained therein as evidence at any future hearing or trial of this matter. Further, the production of the enclosed documents is not, and should not be considered in any manner whatsoever, a waiver of any privilege available to Teva under federal or applicable state law, and the Teva Defendants hereby expressly reserve and preserve each and every privilege available under applicable law.

Please feel free to contact me if you have any questions or concerns.

Respectfully,

/s/ Brian H. Rubenstein  
Brian H. Rubenstein, Esq.  
Attorney for Teva Pharmaceuticals USA,  
Inc., Teva Pharmaceutical Industries Ltd.,  
Actavis LLC, and Actavis Pharma, Inc.

cc: Jessica Priselac, Esq. (*via email, for distribution to Defendants' Counsel*)  
Seth A. Goldberg, Esq. (*via email*)

---

<sup>3</sup> Documents in this production which have been mistakenly labeled "HIGHLY CONFIDENTIAL" were intended to be labeled "RESTRICTED CONFIDENTIAL" and should be treated as "RESTRICTED CONFIDENTIAL" until the documents are reproduced with correct stamping.

Ruben Honik  
David Stanoch  
Adam M. Slater  
Conlee Whiteley  
Daniel Nigh  
Behram Parekh  
July 15, 2020  
Page 5

Clem C. Trischler, Esq. (*via email*)  
Sarah E. Johnston, Esq. (*via email*)  
Lori G. Cohen, Esq. (*via email*)  
Victoria D. Lockard, Esq. (*via email*)  
Steven M. Harkins, Esq. (*via email*)  
Joey Argenal (argenal@csdisco.com) (*via email*)